[HTML][HTML] Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
…, A Tin, R Salari, S Shchegrova, H Pawar, AL Delson… - Annals of …, 2021 - Elsevier
Background Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) is
strongly associated with favorable outcome. We examined the utility of serial circulating tumor …
strongly associated with favorable outcome. We examined the utility of serial circulating tumor …
[PDF][PDF] Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
…, GL Hirst, C Yau, DM Wolf, W Li, AL Delson… - Cancer cell, 2023 - cell.com
Circulating tumor DNA (ctDNA) analysis may improve early-stage breast cancer treatment
via non-invasive tumor burden assessment. To investigate subtype-specific differences in the …
via non-invasive tumor burden assessment. To investigate subtype-specific differences in the …
[HTML][HTML] Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
…, LB Swigart, DC Newitt, J Gibbs, AL Delson… - NPJ Breast …, 2021 - nature.com
We investigated whether serial measurements of circulating tumor DNA (ctDNA) and functional
tumor volume (FTV) by magnetic resonance imaging (MRI) can be combined to improve …
tumor volume (FTV) by magnetic resonance imaging (MRI) can be combined to improve …
Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-line chemotherapy
Background We examined the prognostic significance of circulating tumor cell (CTC)
dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line …
dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line …
Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predicts adverse outcome in early breast cancer
…, CA Ewing, AL Delson, LJ Van't Veer, L Esserman… - Clinical Cancer …, 2019 - AACR
Purpose: We examined the prognostic impact of circulating tumor cells (CTCs) and disseminated
tumor cells (DTCs) detected at the time of surgery in 742 untreated patients with early …
tumor cells (DTCs) detected at the time of surgery in 742 untreated patients with early …
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy
…, GL Hirst, C Yau, DM Wolf, W Li, AL Delson… - Clinical Cancer …, 2024 - AACR
Purpose: We previously demonstrated the clinical significance of circulating tumor DNA (ctDNA)
in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy (…
in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy (…
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage …
…, L Brown Swigart, J Perlmutter, AL Delson… - Breast Cancer Research …, 2023 - Springer
Purpose Disseminated tumor cells (DTCs) expressing epithelial markers in the bone marrow
are associated with recurrence and death, but little is known about risk factors predicting …
are associated with recurrence and death, but little is known about risk factors predicting …
Abstract A50: circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) for monitoring and predicting response to neoadjuvant therapy (NAT) in high-risk …
…, GL Hirst, L Brown-Swigart, AJ Chien, AL Delson… - Clinical Cancer …, 2020 - AACR
Background: MRI measurements (Li et al., Magn Reson Imaging 2019; Hylton et al., Radiology
2016) and ctDNA (Magbanua et al., SABCS 2018) have both been independently shown …
2016) and ctDNA (Magbanua et al., SABCS 2018) have both been independently shown …
Abstract A014: Cell-free DNA concentration as a biomarker of response and recurrence in HER-2 negative breast cancer receiving neoadjuvant chemotherapy
…, GL Hirst, C Yau, DM Wolf, W Li, AL Delson… - Cancer Research, 2024 - AACR
Purpose: Cell-free DNA (cfDNA) shed into the blood by dying cells and its subset—circulating
tumor DNA (ctDNA) exclusively released by tumors—are promising non-invasive …
tumor DNA (ctDNA) exclusively released by tumors—are promising non-invasive …
[PDF][PDF] Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant …
…, M Liu, AL Delson, S Asare, L Esserman… - Data presented at …, 2018 - natera.com
Objectives• Analysis of circulating tumor DNA (ctDNA) offers a minimally invasive approach
for monitoring treatment response and resistance to treatment in patients with breast cancer.
for monitoring treatment response and resistance to treatment in patients with breast cancer.